AIM ImmunoTech is trading at $0.22 (-5.45%) in pre-market with no clear company-specific catalyst for the September 10, 2026 decline.

  • On September 9, the company published a CEO Corner video highlighting Ampligen’s pancreatic-cancer strategy and ongoing Phase 2 DURIPANC progress; it was not reported as negative.
  • Broader markets were mixed, while geopolitical tensions, elevated oil prices and inflation concerns kept sentiment cautious.
  • Recent equity-based debt extinguishment may remain an overhang, but it does not clearly explain today’s move.